KRAS Mutation Test by Sanger Sequencing

Purpose: Detection of activating mutations of KRAS in various neoplasms. KRAS mutant colon cancers are resistant to Cetuximab; KRAS and EGFR mutations are mutually exclusive in lung carcinomas.
CPT Codes: 81275; 88381
Methodology: PCR-Sanger sequencing of DNA obtained from tumor specimens (microdissected to enrich for tumor, less than 40% tumor nuclei).
Turnaround Time: 12 days
Samples tested: Paraffin embedded or frozen tissue containing the carcinoma in question (see solid tumor requisition for detailed specimen requirements).
Forms: 1. PGM Oncology Requisition
2. Medicare Advance Beneficiary Notice